Mitochondrial rRNA blocker

The Mitochondrial rRNA blocker with the sequence GGCAAGTGTTCTTCGGA is designed to target mitochondrial ribosomal RNA (rRNA), specifically blocking the function of 12S or 16S mitochondrial rRNAs. These rRNAs are essential components of the mitochondrial ribosome, which is responsible for translating the 13 key proteins involved in the oxidative phosphorylation pathway, a critical process for cellular energy production. The Reverse Complementary Sequence (5' to 3') is TCCGAAGAACACTTGCC.

Function:

This rRNA blocker works by binding to a complementary sequence within the mitochondrial rRNA, potentially inhibiting the function of the mitochondrial ribosome. This interference can block the translation of mitochondrial-encoded proteins, potentially resulting in impaired mitochondrial function.

Applications:

1. Mitochondrial Dysfunction Studies: Researchers use such blockers to study the role of mitochondria in various diseases, particularly those related to energy production disorders, such as mitochondrial myopathies or neurodegenerative diseases like Parkinson's and Alzheimer's.

2. Cancer Research: Mitochondrial rRNA modification and translation are key processes that can be manipulated in cancer research, especially in understanding how mitochondria contribute to the metabolism and survival of cancer cells. By using blockers to inhibit mitochondrial rRNA, researchers can explore the effects of impaired mitochondrial function on cancer cell growth and treatment responses.

3. Phylogenetic Studies: Mitochondrial rRNA genes, such as 12S and 16S, are also used as molecular markers for studying evolutionary relationships between species. Blockers targeting these rRNAs can aid in experimental setups designed to understand the role of these genes in evolution.

This tool is crucial for mitochondrial research, providing insights into the regulatory mechanisms of mitochondrial gene expression and the broader implications of mitochondrial function in health and disease.

Mitochondrial rRNA blocker is a 17-residue synthetic peptide with the sequence Gly-Gly-Cys-Ala-Ala-Gly-Thr-Gly-Thr-Thr-Cys-Thr-Thr-Cys-Gly-Gly-Ala. The sequence contains 3 cysteine residues, providing potential thiol/disulfide chemistry when the thiol is available; is Gly/Pro-rich, a composition that can influence local backbone flexibility. These sequence-derived properties describe the reagent chemically; no specific receptor, enzyme, pathway, disease association, or biological activity is assigned without product-specific experimental evidence.

• thiol-selective conjugation or immobilization studies
• LC-MS/HPLC analytical method development
• sequence-specific assay controls

Sequence-derived chemical properties support reagent selection and experimental planning but do not establish biological function. Solubility, aggregation, adsorption, conjugation efficiency, and assay performance should be validated under the intended experimental conditions.